Emerging Role of Chimeric Antigen Receptor-Natural Killer Cells for the Treatment of Hematologic Malignancies
Open Access
Abstract
The clinical use of T lymphocytes engineered with chimeric antigen receptors (CARs) has revolutionized the treatment of patients with refractory or relapsed hematological malignancies. CAR natural killer (CAR-NK) cells are NK cells engineered with CARs to specifically target cell antigens expressed on the membrane of tumor cells. CAR-NK cells could offer some advantages with respect to CAR-T cells, related to their specific and innate anti-tumor activity, availability as an “off the shelf” cellular therapy, reduced costs, and improved safety. Promising efficacy of CAR-Nk cell therapy was observed in clinical trials based on the treatment of some hematological malignancies. However, to date, the clinical experience of CAR-NK cell therapy has been preliminary, with the evaluation of only a limited number of patients. Furthermore, CAR-NK cell therapy has been limited by the short persistence of these cells and by the suboptimal cytotoxic activity of some CAR-NK preparations. Therefore, studies based on the enrollment of a number of patients is required to carefully assess and confirm the safety and the efficacy of CAR-NK cell therapy in hematological malignancies and to compare their efficacy with respect to allogeneic CAR-T cells.Keywords
This publication has 89 references indexed in Scilit:
- Novel treatment strategies for hematological malignancies in the immunotherapy eraInternational Journal of Hematology, 2024
- Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuitsCell Reports, 2024
- Results of a phase I trial with Haploidentical mbIL‐21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AMLAmerican Journal of Hematology, 2024
- A pilot study of cord blood-derived natural killer cells as maintenance therapy after autologous hematopoietic stem cell transplantationAnnals of Hematology, 2023
- Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell LymphomaTransplantation and Cellular Therapy, 2023
- Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particlesMolecular Therapy - Methods & Clinical Development, 2023
- Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapyMolecular Therapy-Oncolytics, 2022
- Human natural killer cells: Form, function, and developmentJournal of Allergy and Clinical Immunology, 2022
- Tissue Determinants of Human NK Cell Development, Function, and ResidenceCell, 2020
- The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activationHuman Immunology, 2012